These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29976287)

  • 1. Global Prospective Safety Analysis of Rivaroxaban.
    Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
    J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
    Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America.
    Martínez CAA; Lanas F; Radaideh G; Kharabsheh SM; Lambelet M; Viaud MAL; Ziadeh NS; Turpie AGG;
    Egypt Heart J; 2018 Dec; 70(4):307-313. PubMed ID: 30591748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea.
    Shim J; On YK; Kwon SU; Nam GB; Lee MH; Park HW; Hong KS; Kim NH; Amarenco P; Rha SW; Shin DG; Rha JH; Kim YH
    Korean J Intern Med; 2021 Jul; 36(4):906-913. PubMed ID: 32872740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
    Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
    Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.
    Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG; Camm AJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):70-79. PubMed ID: 30423165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.
    Kirchhof P; Haas S; Amarenco P; Hess S; Lambelet M; van Eickels M; Turpie AGG; Camm AJ;
    J Am Heart Assoc; 2020 Mar; 9(5):e009530. PubMed ID: 32079476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia.
    Kim YH; Shim J; Tsai CT; Wang CC; Vilela G; Muengtaweepongsa S; Kurniawan M; Maskon O; Li Fern H; Nguyen TH; Thanachartwet T; Sim K; Camm AJ;
    J Arrhythm; 2018 Aug; 34(4):418-427. PubMed ID: 30167013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
    Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Ohashi Y; Okayama Y; Sunaya T; Yamanaka S
    J Cardiol; 2019 Jul; 74(1):60-66. PubMed ID: 30745002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF.
    Blumer V; Rivera M; Corbalán R; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Hellkamp AS; Singer DE; Fox KAA; Patel MR
    Am Heart J; 2021 Jun; 236():4-12. PubMed ID: 33571477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS.
    Kirchhof P; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ
    Europace; 2024 Jul; 26(7):. PubMed ID: 38941511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
    Kitazono T; Ikeda T; Ogawa S; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Cavaliere M; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
    Liu PY; Choi EK; Kim TS; Kuo JY; Lee JM; On YK; Park SW; Park HW; Shin DG; Wang L; Yen HW; Lee MH;
    Adv Ther; 2022 Jul; 39(7):3316-3333. PubMed ID: 35616848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban.
    Camm AJ; Coleman CI; Larsen TB; Nielsen PB; Tamayo CS
    Thromb Haemost; 2018 May; 118(S 01):S45-S60. PubMed ID: 29566414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study.
    Camm AJ; Amarenco P; Haas S; Bach M; Kirchhof P; Kuhls S; Lambelet M; Turpie AGG;
    Clin Cardiol; 2020 Dec; 43(12):1405-1413. PubMed ID: 32896928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.